Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer, Genomic Solutions in Proteomics Distribution Pact

NEW YORK, March 17 - PerkinElmer Life and Analytical Sciences and the Genomic Solutions subsidiary of Harvard Biosciences have entered a distribution agreement for an assortment of proteomics-related technology, the companies said today.


The agreement, effective Jan. 1, 2003, gives PerkinElmer worldwide distribution rights to products that Genomic Solutions will manufacture exclusively for PerkinElmer: the ProXcision proteomics gel cutting robot, and the HybArray 12 DNA hybridization workstation.


The arrangement also gives Genomic Solutions the right to distribute the Proteome 1D analyzer software developed by Nonlinear Dynamics for PerkinElmer.


PerkinElmer, which estimates that the worldwide proteomics market is growing by nearly 40 percent annually, said the agreement would flesh out its proteomics technology offering by adding a gel spot cutter to a suite of tools that currently includes the ProXpress proteomics imaging system, MultiProbe II proteomics workstation for protein digestion and MALDI spotting, TOFprep MALDI spotting system, and prOTOF 2000 MALDI O-TOF mass spectrometer from PerkinElmer and MDS Sciex.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.